Manuel “Manny” Iglesias, President of Healthtech Solutions Inc.
Manuel “Manny” Iglesias is a prominent serial entrepreneur, organizational executive, and legal professional, who has distinguished himself with major leadership roles in business, law, and politics.
Starting with a Bachelor of Science in Foreign Services from Georgetown University School of Foreign Service, he went on to receive his J.D. degree and MBA from the University of Chicago. His education also includes the study of German at the Goethe Institute in Germany and Austria, as well as the study of French at the University of Lausanne in Switzerland.
From there Mr. Iglesias held increasingly responsible positions in a number of law firms, dealing with healthcare and business transactions on both a national and international level. Among other things, Mr. Iglesias represented clients involved in international business before U.S. Government agencies, and negotiations between South American governments while specializing in mergers and acquisitions, financial transactions, and healthcare. He also worked for two years as a Presidential Appointee with the U.S. Department of Agriculture in Washington, DC, representing the Department on the White House committee on immigration reform.
Industry roles include being Founder/President of Hygea Health Holding, Inc. (2007 – 2018), with revenues during his tenure topping $250 million, served as Chairman of the Board of Organicell Regenerative Medicine Inc. symbol BPSR. Other positions include Chairman/CEO of Management and Business Associates, LLC, Founder/President of Capital International SBIC, L.P., and President/CEO of Carnes Cibao, SA.
Mr. Iglesias is currently the president of Healthtech Solutions Inc. (Symbol HLTT), president of MediScan, Inc., a subsidiary of Healthtech Solutions Inc. MediScan’s standout technology can turn 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The goal is a commercial system that can do more than an X-ray, MRI, or CT scan, without radiation and at a lower cost. The target is a $30 billion slice of the overall $130 billion imaging market. In addition, the parent company, Healthtech Solutions, has announced the incorporation of a new subsidiary, RevHeart, advancing critical research into the treatment of COVID-related heart muscle injury. All of Healthtech’s over-arching vision of investing in and promoting cutting edge healthcare technologies that otherwise may not be funded and make it to market.